REVIEW
Year : 2017 | Volume
: 2 | Issue : 1 | Page : 7--11
Impact of incretin-related agents on endothelial cell function
Hiroshi Nomoto1, Hideaki Miyoshi1, Akinobu Nakamura1, Tatsuya Atsumi1, Naoki Manda2, Yoshio Kurihara3, Shin Aoki4, on behalf of SAIS Study Group5 1 Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan 2 Manda Memorial Hospital, Sapporo, Japan 3 Kurihara Clinic, Sapporo, Japan 4 Aoki Clinic, Sapporo, Japan 5 The membership of the SAIS Study Group is provided in the Acknowledgements
Correspondence Address:
Hideaki Miyoshi Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo Japan
Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence.
How to cite this article:
Nomoto H, Miyoshi H, Nakamura A, Atsumi T, Manda N, Kurihara Y, Aoki S, on behalf of SAIS Study Group. Impact of incretin-related agents on endothelial cell function.Clin Trials Degener Dis 2017;2:7-11
|
How to cite this URL:
Nomoto H, Miyoshi H, Nakamura A, Atsumi T, Manda N, Kurihara Y, Aoki S, on behalf of SAIS Study Group. Impact of incretin-related agents on endothelial cell function. Clin Trials Degener Dis [serial online] 2017 [cited 2024 Mar 29 ];2:7-11
Available from: https://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2017;volume=2;issue=1;spage=7;epage=11;aulast=Nomoto;type=0 |
|